Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 13/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13527237 | 0.96 | CYP2D6 (0.64) | CYP2D6CYP3A4CYP2C9CYP2C19CYP19A1 | |
| SCHEMBL5583851 | 0.84 | CYP2D6 (0.76) | CYP2D6CYP3A4CYP2C9CYP2C19CYP19A1 | |
| SCHEMBL9151170 | 0.84 | CYP2D6 (0.76) | CYP2D6CYP3A4CYP2C9CYP2C19CYP19A1 | |
| SCHEMBL21157729 | 0.83 | RARB (0.52) | CYP2D6CYP3A4CYP2C9CYP2C19CYP19A1 | |
| SCHEMBL13526917 | 0.83 | CYP2D6 (0.49) | CYP2D6CYP3A4CYP2C9CYP2C19CYP19A1 | |
| SCHEMBL24271048 | 0.82 | CYP2D6 (0.52) | CYP2D6CYP3A4CYP2C9CYP2C19CYP19A1 | |
| SCHEMBL14129958 | 0.81 | CYP2D6 (1.00) | CYP2D6CYP3A4CYP2C9CYP2C19CYP19A1 | |
| SCHEMBL14129887 | 0.81 | CYP2D6 (1.00) | CYP2D6CYP3A4CYP2C9CYP2C19CYP19A1 | |
| SCHEMBL10022022 | 0.80 | CYP2D6 (0.70) | CYP2D6CYP3A4CYP2C9CYP2C19CYP19A1 | |
| SCHEMBL6905782 | 0.80 | CYP2D6 (0.70) | CYP2D6CYP3A4CYP2C9CYP2C19CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349621-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2017-12-07 | — | — | US | disclosed |
| US-20160152654-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-06-02 | — | — | US | disclosed |
| US-9085600-B2 | Triazole compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140094422-A1 | Triazole Compounds and Methods of Making and Using the Same | SILICON VALLEY BANK | 2014-04-03 | — | — | US | disclosed |
| US-8470985-B2 | Triazole compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349621-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | CYP2D6 285/4885CYP3A4 84/4885CYP2C9 346/4885 |
| US-20140094422-A1 | Triazole Compounds and Methods of Making and Using the Same | PROKR1, ARG1, ARG2 | CYP2D6 285/4885CYP3A4 84/4885CYP2C9 346/4885 |
| US-20160152654-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | CYP2D6 285/4885CYP3A4 84/4885CYP2C9 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.